27 January 2012 - GlaxoSmithKline plc (LON:GSK) said today that three of its board members will not stand for re-election to the board at the annual general shareholder meeting in 2013.

Specifically, Crispin Davis, Robert Wilson and Larry Culp will step down next year after nine years of service at the board.

Additionally, James Murdoch has decided to leave the board at the company's annual shareholder meeting in 2012. Murdoch wants to focus on current duties as non-executive chairman of BSkyB and to relocate to the USA as chairman and CEO of News Corp, the company said.

The board has also picked successors of the three board members on the committees on which they serve.

Tom de Swaan will succeed Crispin Davis as chairman of the remuneration committee, effective 1 January 2013. Judy Lewent will succeed Tom de Swaan as chair of the audit and risk committee with effect on 1 January 2013. Swaan will remain member of this committee.

Deryck Maughan will succeed Robert Wilson as senior independent non-executive director with effect from the closure of GSK's annual general meeting in 2013, the company said.